Abstract
Background:
Adiponectin is an anti-inflammatory and potentially antiatherogenic molecule. Some recent reports suggest that tumour necrosis factor alpha (TNFalpha) blockade therapy increases circulating adiponectin levels, but data are sparse and inconsistent.
Methods:
Data from a double-blind placebo controlled study of onercept in 126 patients with psoriatic arthritis (PsA) and from pre- and post-adalimumab treatment in 171 patients with rheumatoid arthritis (RA) were used to examine the effect of TNFalpha blockade therapy on adiponectin.
Results:
Despite expected associations of adiponectin with gender and baseline high-density lipoprotein cholesterol and triglyceride, adiponectin levels did not change over time with TNFalpha blockade therapy in either group. The mean+/-SD absolute change in adiponectin levels was -0.23+/-4.6 microg/ml in patients with PsA treated with combined onercept 50 mg and onercept 100 mg (vs placebo, p=0.60) and 0.28+/-3.23 microg/ml in patients with RA treated with adalimumab (vs baseline, p=0.66).
Conclusion:
These results do not support a significant effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adalimumab
-
Adiponectin / blood*
-
Adult
-
Aged
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents / pharmacology*
-
Antirheumatic Agents / therapeutic use
-
Arthritis, Psoriatic / blood*
-
Arthritis, Psoriatic / complications
-
Arthritis, Psoriatic / drug therapy
-
Arthritis, Rheumatoid / blood
-
Arthritis, Rheumatoid / complications
-
Arthritis, Rheumatoid / drug therapy
-
Autoimmune Diseases / blood*
-
Autoimmune Diseases / complications
-
Autoimmune Diseases / drug therapy
-
Cardiovascular Diseases / etiology
-
Epidemiologic Methods
-
Female
-
Humans
-
Lipids / blood
-
Male
-
Middle Aged
-
Receptors, Tumor Necrosis Factor, Type I / pharmacology
-
Receptors, Tumor Necrosis Factor, Type I / therapeutic use
-
Tumor Necrosis Factor Decoy Receptors / pharmacology
-
Tumor Necrosis Factor Decoy Receptors / therapeutic use
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Adiponectin
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Lipids
-
Receptors, Tumor Necrosis Factor, Type I
-
Tumor Necrosis Factor Decoy Receptors
-
Tumor Necrosis Factor-alpha
-
recombinant human tumor necrosis factor-binding protein-1
-
Adalimumab